Kairos Pharma CEO to Present at H.C. Wainwright Conference, Highlighting Lead Drug Candidate ENV-105

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company dedicated to addressing cancer drug resistance, announced that its CEO and Chairman, John Yu, MD, will deliver a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference. The event is scheduled to take place from Sept. 14-16, 2026, at the Lotte New York Palace Hotel. This presentation provides a platform for the company to showcase its innovative approach to oncology therapeutics to a broad investment audience.

The announcement is significant because it highlights Kairos Pharma's progress in a field where drug resistance remains a major hurdle in effective cancer treatment. The company's lead candidate, ENV-105, is an antibody targeting CD105, a protein implicated in resistance and disease relapse following standard therapies. By aiming to reverse drug resistance, ENV-105 could potentially restore the efficacy of existing treatments across multiple cancer types, offering new hope for patients who have limited options after standard care fails.

Kairos Pharma, headquartered in Los Angeles, utilizes structural biology to design therapeutics that attack the mechanisms of resistance and immune suppression. This scientific approach distinguishes the company in the competitive oncology landscape. The presentation at the H.C. Wainwright conference is an opportunity for investors to gain insights into the company's strategic direction and the clinical development of ENV-105.

For those interested in the full details of the press release, additional information is available at https://ibn.fm/NrBQD. The company also maintains a newsroom with the latest updates at https://ibn.fm/KAPA.

The participation in this prestigious conference underscores Kairos Pharma's commitment to advancing its pipeline and engaging with the investment community. As the company continues to develop ENV-105, the outcomes of upcoming trials will be closely watched by stakeholders. The ability to overcome drug resistance could mark a significant advancement in oncology, potentially improving survival rates and quality of life for cancer patients worldwide.